STOCKHOLM -- The latest European Society of Cardiology guidelines for revascularization in myocardial infarction patients recommend the use of ticagrelor (Brilinta) -- an antiplatelet agent that has not yet been approved by any regulatory agency -- as a recommended antithrombotic treatment.
